Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450.
Sumnall
H R
HR
Centre for Public Health, Liverpool John Moores University, 70 Great Crosshall Street, L3 2AB, Liverpool, UK. h.sumnall@livjm.ac.uk
Jerome
L
L
Doblin
R
R
Mithoefer
M C
MC
D000818:Animals; D004298:Dopamine / Q000378:metabolism*; D006213:Hallucinogens / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D013287:Illicit Drugs / Q000009:adverse effects; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000008:administration & dosage* / Q000009:adverse effects; D020258:Neurotoxicity Syndromes / Q000209:etiology* / Q000378:metabolism; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000378:metabolism; D011323:Primates; D011596:Psychomotor Disorders / Q000139:chemically induced* / Q000378:metabolism; D013045:Species Specificity
D006213:Hallucinogens; D013287:Illicit Drugs; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D004298:Dopamine